Market Overview
CRISPR-based POC diagnostics combine the precision of CRISPR gene-editing with the convenience of point-of-care testing, enabling rapid detection of pathogens, genetic mutations, and biomarkers without centralized laboratory infrastructure. The market encompasses products including CRISPR enzymes, detection kits, reagents, and associated software libraries, with applications spanning infectious diseases, oncology, and genetic disorders. Despite the current 0.0% annual growth rate, the segment represents a significant opportunity as healthcare systems increasingly prioritize rapid, accurate diagnostics.
- •Market valued at $8.5 billion globally in 2025
- •Products include enzymes, kits & reagents, and software libraries
- •Applications cover infectious disease, oncology, and genetic testing
Growth Drivers
The primary growth driver is the escalating demand for rapid and accurate diagnostic solutions, particularly for infectious diseases, where CRISPR-based tests can deliver results in under an hour with high sensitivity and specificity. Technological advancements in CRISPR systems, including the development of Cas12 and Cas13 variants, have expanded the capabilities of POC devices beyond DNA detection to include RNA targets. Additionally, the COVID-19 pandemic highlighted the critical need for decentralized testing infrastructure, accelerating investment and regulatory approval for CRISPR-based diagnostic platforms.
- •Demand for rapid infectious disease detection
- •Technological improvements in Cas12 and Cas13 systems
- •Pandemic-driven need for decentralized testing infrastructure
Segmentation and Regional Analysis
The market is segmented by product type (enzymes, kits and reagents, software and libraries), technology (Cas9, Cas12, Cas13), application (infectious disease, oncology, genetic disorders), end-use (hospitals, clinics, diagnostic laboratories), and region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa). North America currently dominates the market due to strong R&D infrastructure, favorable regulatory pathways, and high adoption of advanced medical technologies. The Asia-Pacific region is expected to witness significant growth driven by increasing healthcare expenditure, large patient populations, and growing investments in biotechnology research.
- •Segmented by product, technology, application, end-use, and region
- •North America leads in market share
- •Asia-Pacific projected for significant growth
Trends and Outlook
What are the recent trends and outlook?
Current trends include the miniaturization of CRISPR diagnostic devices for truly portable use, integration with smartphone-based readout systems, and the development of multiplexed assays capable of detecting multiple pathogens simultaneously. The outlook suggests continued innovation in CRISPR-based POC diagnostics, with potential applications expanding to areas such as at-home testing, food safety, and environmental monitoring. Regulatory approvals and cost reductions will be critical factors in determining the market's future growth trajectory beyond the current 0.0% annual growth rate.
- •Miniaturization and smartphone integration for portable testing
- •Multiplexed assays for simultaneous multi-pathogen detection
- •Expanding applications to at-home and environmental testing
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.